DE69330626T2 - Piperazin- und Homopiperazinderivate, diese enthaltende pharmazeutische Präparate und Verfahren zu ihrer Herstellung - Google Patents

Piperazin- und Homopiperazinderivate, diese enthaltende pharmazeutische Präparate und Verfahren zu ihrer Herstellung

Info

Publication number
DE69330626T2
DE69330626T2 DE69330626T DE69330626T DE69330626T2 DE 69330626 T2 DE69330626 T2 DE 69330626T2 DE 69330626 T DE69330626 T DE 69330626T DE 69330626 T DE69330626 T DE 69330626T DE 69330626 T2 DE69330626 T2 DE 69330626T2
Authority
DE
Germany
Prior art keywords
piperazine
preparation
pharmaceutical preparations
preparations containing
homopiperazine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330626T
Other languages
English (en)
Other versions
DE69330626D1 (de
Inventor
Zoltan Dr Zubovics
Nee Horvath Katali Goldschmidt
Nee Farago Katalin Dr Szilagyi
Andrasi Dr Ferenc
Nee Szentkuti Eszter Dr Hodula
Lajos Dr Toldy
Klara Dr Sutka
Zsuzsanna Fittler
Laszlo Sebestyen
Nee Kiss Katalin Dr Goergenyi
Istvan Dr Sziraki
Jozsef Dr Gyimesi
Nee Kardos Valeria Vitkoczi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nisshin Seifun Group Inc
Original Assignee
Nisshin Seifun Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nisshin Seifun Group Inc filed Critical Nisshin Seifun Group Inc
Application granted granted Critical
Publication of DE69330626D1 publication Critical patent/DE69330626D1/de
Publication of DE69330626T2 publication Critical patent/DE69330626T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69330626T 1992-06-17 1993-06-17 Piperazin- und Homopiperazinderivate, diese enthaltende pharmazeutische Präparate und Verfahren zu ihrer Herstellung Expired - Fee Related DE69330626T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9202021A HU214331B (hu) 1992-06-17 1992-06-17 Eljárás piperazin- és homopiperazinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására

Publications (2)

Publication Number Publication Date
DE69330626D1 DE69330626D1 (de) 2001-09-27
DE69330626T2 true DE69330626T2 (de) 2002-07-04

Family

ID=10982070

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330626T Expired - Fee Related DE69330626T2 (de) 1992-06-17 1993-06-17 Piperazin- und Homopiperazinderivate, diese enthaltende pharmazeutische Präparate und Verfahren zu ihrer Herstellung

Country Status (7)

Country Link
US (1) US5380724A (de)
EP (1) EP0574906B1 (de)
JP (1) JP3247769B2 (de)
KR (1) KR940005625A (de)
CA (1) CA2098562A1 (de)
DE (1) DE69330626T2 (de)
HU (1) HU214331B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171674B1 (en) 1993-07-20 2001-01-09 Semiconductor Energy Laboratory Co., Ltd. Hard carbon coating for magnetic recording medium
US6835523B1 (en) 1993-05-09 2004-12-28 Semiconductor Energy Laboratory Co., Ltd. Apparatus for fabricating coating and method of fabricating the coating
HUT76265A (en) * 1995-10-19 1997-07-28 Gyogyszerkutato Intezet Pyrimidine derivatives, pharmaceutical compositions containing them, process for producing them and their use
US7276506B2 (en) * 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
AU2003291141A1 (en) * 2002-12-03 2004-06-23 Epcellon, Inc. 5-nitroso-6-piperazinyl-pyrimidine derivatives for treating ischemia
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
ES2293354T3 (es) * 2003-10-17 2008-03-16 4 Aza Ip Nv Derivados de pteridina sustituidos por heterociclos y su uso en terapia.
GB2407089A (en) * 2003-10-17 2005-04-20 4 Aza Bioscience Nv Pteridine derivatives
US20050113573A1 (en) * 2003-11-21 2005-05-26 Toledo Luis H. Nitroso compounds to treat ischemia
JP4571561B2 (ja) 2005-09-08 2010-10-27 トーカロ株式会社 耐プラズマエロージョン性に優れる溶射皮膜被覆部材およびその製造方法
US10144736B2 (en) * 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
DE102008018967A1 (de) 2008-04-16 2009-10-22 Ticona Gmbh Oxymethylenpolymere, Verfahren zu deren Herstellung und deren Verwendung
US8840976B2 (en) 2010-10-14 2014-09-23 Ticona Llc VOC or compressed gas containment device made from a polyoxymethylene polymer
EP2505609B1 (de) 2011-04-01 2015-01-21 Ticona GmbH Polyoxymethylen mit hoher schlagfestigkeit für extrusionsblasformung
US8968858B2 (en) 2011-12-30 2015-03-03 Ticona Llc Printable molded articles made from a polyoxymethylene polymer composition
EP2938674A1 (de) 2012-12-27 2015-11-04 Ticona LLC Schlagzähmodifizierte polyoxymethylenzusammensetzung und daraus hergestellte artikel mit stabilität bei exposition gegenüber uv-licht
JP6047830B2 (ja) * 2013-03-12 2016-12-21 花王株式会社 ホモピペラジン誘導体を含む漂白剤組成物
RS56787B1 (sr) 2015-03-04 2018-04-30 Gilead Sciences Inc Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN110041291B (zh) * 2018-01-15 2021-02-26 北京采瑞医药科技研究院有限公司 一种玛咖酰胺衍生物及其制备方法
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1256513A (de) * 1968-10-02 1971-12-08
NL7103449A (de) * 1971-03-15 1972-09-19
CA979894A (en) * 1972-09-18 1975-12-16 Science Union Et Cie, Societe Francaise De Recherche Medicale Procede de preparation de derives du benzodioxole
CA983495A (en) * 1972-10-11 1976-02-10 Gilbert Regnier Procede de preparation de derives du benzodioxole
CA983493A (en) * 1972-10-11 1976-02-10 Gilbert Regnier Procede de preparation des derives du benzodioxole
CA983494A (en) * 1972-10-11 1976-02-10 Gilbert Regnier Procede de preparation des derives du benzodioxole
JPS4972271A (de) * 1972-11-14 1974-07-12
JPS4972273A (de) * 1972-11-14 1974-07-12
JPS4972270A (de) * 1972-11-14 1974-07-12
JPS4972272A (de) * 1972-11-14 1974-07-12
CA983497A (en) * 1972-11-28 1976-02-10 Gilbert Regnier Procede de preparation des derives de la s-triazine
JPS4976887A (de) * 1972-11-29 1974-07-24
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4252809A (en) * 1977-01-03 1981-02-24 Rohm Pharma Gmbh Substituted pteridine compounds and pharmaceutical compositions containing the same
DE2700073A1 (de) * 1977-01-03 1978-07-13 Roehm Pharma Gmbh Pteridinverbindungen mit pharmazeutischer wirksamkeit
US4351832A (en) * 1980-04-18 1982-09-28 American Home Products Corporation 2-(Piperazinyl)-4-pyrimidinamines
DE3407695A1 (de) * 1984-03-02 1985-09-12 Röhm Pharma GmbH, 6108 Weiterstadt Pteridinverbindungen mit pharmazeutischer wirksamkeit
WO1987001706A2 (en) * 1985-09-12 1987-03-26 The Upjohn Company C20 through c26 amino steroids
DE3540653A1 (de) * 1985-11-13 1987-05-14 Schering Ag Neue 3-oxadiazol- und 3-carbonsaeure-ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
JPH0667838B2 (ja) * 1985-12-25 1994-08-31 三菱化成株式会社 過酸化脂質生成抑制剤
JPH0560831B1 (de) * 1986-06-17 1993-09-03 Dainippon Pharmaceutical Co
WO1987007895A1 (en) * 1986-06-23 1987-12-30 The Upjohn Company Androstane-type and cortical aminoesters
LU86695A1 (fr) * 1986-12-01 1988-07-14 Oreal Nouveaux derives de piperazinyl-1 pyrimidine,leur preparation et leur application en therapeutique et cosmetique
AU1704588A (en) * 1987-04-03 1988-11-02 Upjohn Company, The Amino-9,10-secosteroids
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
JPS63270678A (ja) * 1987-04-30 1988-11-08 Mitsui Petrochem Ind Ltd 新規含窒素化合物
JPS6442472A (en) * 1987-08-10 1989-02-14 Kanebo Ltd Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
KR890011868A (ko) * 1988-01-26 1989-08-23 원본미기재 간질환 치료제 및 피페라진 유도체
JP2587979B2 (ja) * 1988-03-08 1997-03-05 日本ケミファ株式会社 テルペン系化合物
JPH0730058B2 (ja) * 1988-05-14 1995-04-05 参天製薬株式会社 ３−オキソ−１，４−ベンゾチアジン誘導体
FR2644788B1 (fr) * 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2644787B1 (fr) * 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 21 aminosubstitues, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2655649B1 (fr) * 1989-12-12 1994-07-08 Adir Nouveaux derives de la piperidine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
FR2659656B1 (fr) * 1990-03-15 1994-09-09 Sanofi Sa Derives de pyrimidinedione-2,4 et medicaments les contenant.
EP0446539A1 (de) * 1990-03-16 1991-09-18 Merrell Dow Pharmaceuticals Inc. Ascorbinsäure-Derivate

Also Published As

Publication number Publication date
JPH06179673A (ja) 1994-06-28
US5380724A (en) 1995-01-10
CA2098562A1 (en) 1993-12-18
JP3247769B2 (ja) 2002-01-21
EP0574906A2 (de) 1993-12-22
HU9202021D0 (en) 1992-09-28
EP0574906A3 (de) 1994-04-13
HUT64333A (en) 1993-12-28
HU214331B (hu) 1998-03-02
EP0574906B1 (de) 2001-08-22
DE69330626D1 (de) 2001-09-27
KR940005625A (ko) 1994-03-22

Similar Documents

Publication Publication Date Title
DE69330626D1 (de) Piperazin- und Homopiperazinderivate, diese enthaltende pharmazeutische Präparate und Verfahren zu ihrer Herstellung
DE69131813D1 (de) Amido-3-Pyrazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
DE68908786T2 (de) Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
DE68913831T2 (de) Kondensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
DE69017479D1 (de) Azabicycloheptenderivate und ihre Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende Zubereitungen.
ATE215951T1 (de) Tetracyclische campothecineanalogue, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen
ATE46900T1 (de) Phenylethanolaminotetraline, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69219394D1 (de) Heterozyklische Alkylamide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE3788261T2 (de) Cephemderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate.
DE3852145D1 (de) Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
DE69008566T2 (de) Pyridazin-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
DE69326569T2 (de) Sterinderivate, Verfahren zu ihrer Herstellung und dermatologische Präparate
DE69028602D1 (de) Pyridazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
ATE58538T1 (de) 4-chinolon-3-carbonsaeurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE68914471T2 (de) Thieno[2,3-d]azepinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
DE3868309D1 (de) Imidazol-derivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammenstellungen und deren anwendung als arzneimittel.
ATE41654T1 (de) All-cis-1,3,5-triamino2,4,6-cyclohexantriolderivate, ihre verwendung, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
DE3670635D1 (de) Neue benzisoselenazolonyl-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ATE57935T1 (de) 16,17-acetalsubstituierte pregnan-21-saeure, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate.
ATA22388A (de) Neue benzimidazolverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
ATE52254T1 (de) Neue benzisoselenazolonyl-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ATE105284T1 (de) Pyridazin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ATE50579T1 (de) Substituierte spiropyridinderivate, diese enthaltende pharmazeutische zubereitungen, verfahren zu ihrer herstellung und zubereitungen.
ATE93858T1 (de) Condensierte pyrimidinderivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ATE102945T1 (de) Kondensierte pyrimidinderivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NISSHIN SEIFUN GROUP INC., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee